Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Bio-Techne Corporation stock

Learn how to easily invest in Bio-Techne Corporation stock.

Bio-Techne Corporation is a biotechnology business based in the US. Bio-Techne Corporation shares (TECH) are listed on the NASDAQ and all prices are listed in US Dollars. Bio-Techne Corporation employs 2,600 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Bio-Techne Corporation

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – TECH – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Bio-Techne Corporation stock price (NASDAQ: TECH)

Use our graph to track the performance of TECH stocks over time.

Bio-Techne Corporation shares at a glance

Information last updated 2022-01-18.
Latest market close$367.10
52-week range$310.11 - $543.50
50-day moving average $474.52
200-day moving average $464.91
Wall St. target price$549.70
PE ratio 89.9493
Dividend yield $1.28 (0.33%)
Earnings per share (TTM) $4.34

Buy Bio-Techne Corporation shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
M1 Finance
Free 1-year trial of M1 Plus
when you sign up for M1 Finance
Invest in your favorite stocks or in curated portfolios with automatic rebalancing.
SoFi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in most equities.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
$10 of crypto
Open an account with access to crypto
A platform built for all kinds of traders and all styles of trading
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Stash Invest
Stocks, ETFs
$1 per month
Add at least $5 to your Invest account
Stash is more than an investment app. You’ll have access to tools that can help you become a confident investor.
Stocks, ETFs, Cryptocurrency
$0 per month
Download and sign up with; approved accounts receive a free stock slice worth up to $300, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Bio-Techne Corporation stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Bio-Techne Corporation price performance over time

Historical closes compared with the close of $367.1 from 2022-01-21

1 week (2022-01-14) -5.90%
1 month (2021-12-23) -25.79%
3 months (2021-10-22) -27.34%
6 months (2021-07-23) -22.62%
1 year (2021-01-22) 2.95%
2 years (2020-01-23) 67.81%
3 years (2019-01-23) 126.42%
5 years (2017-01-23) 274.97%

Is Bio-Techne Corporation stock undervalued or overvalued?

Valuing Bio-Techne Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Bio-Techne Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Bio-Techne Corporation's P/E ratio

Bio-Techne Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 90x. In other words, Bio-Techne Corporation shares trade at around 90x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Bio-Techne Corporation's PEG ratio

Bio-Techne Corporation's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.7204. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Bio-Techne Corporation's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Bio-Techne Corporation's EBITDA

Bio-Techne Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $315.3 million.

The EBITDA is a measure of a Bio-Techne Corporation's overall financial performance and is widely used to measure a its profitability.

Bio-Techne Corporation financials

Revenue TTM $984.6 million
Operating margin TTM 26.45%
Gross profit TTM $634.4 million
Return on assets TTM 7.53%
Return on equity TTM 11.35%
Profit margin 17.94%
Book value $41.74
Market capitalisation $15.3 billion

TTM: trailing 12 months

Bio-Techne Corporation share dividends


Dividend payout ratio: 18% of net profits

Recently Bio-Techne Corporation has paid out, on average, around 18% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.33% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Bio-Techne Corporation shareholders could enjoy a 0.33% return on their shares, in the form of dividend payments. In Bio-Techne Corporation's case, that would currently equate to about $1.28 per share.

While Bio-Techne Corporation's payout ratio might seem low, this can signify that Bio-Techne Corporation is investing more in its future growth.

Bio-Techne Corporation's most recent dividend payout was on 25 November 2021. The latest dividend was paid out to all shareholders who bought their shares by 9 November 2021 (the "ex-dividend date").

Have Bio-Techne Corporation's shares ever split?

Bio-Techne Corporation's shares were split on a 2:1 basis on 3 December 2000. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Bio-Techne Corporation shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Bio-Techne Corporation shares which in turn could have impacted Bio-Techne Corporation's share price.

Bio-Techne Corporation share price volatility

Over the last 12 months, Bio-Techne Corporation's shares have ranged in value from as little as $310.1123 up to $543.5034. A popular way to gauge a stock's volatility is its "beta".

TECH.US volatility(beta: 1.15)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Bio-Techne Corporation's is 1.1465. This would suggest that Bio-Techne Corporation's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Bio-Techne Corporation overview

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, and diagnostics and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment provides biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment provides diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and nucleic acid analysis products for use in diagnostic or research applications, as well as instruments and process control products for hematology, blood chemistry, blood gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Novus Biologicals, Tocris Biosciences, ProteinSimple, Advanced Cell Diagnostics, and ExosomeDx brands. Bio-Techne Corporation has a clinical research collaboration with Carterra Inc.

Frequently asked questions

What percentage of Bio-Techne Corporation is owned by insiders or institutions?
Currently 0.642% of Bio-Techne Corporation shares are held by insiders and 94.637% by institutions.
How many people work for Bio-Techne Corporation?
Latest data suggests 2,600 work at Bio-Techne Corporation.
When does the fiscal year end for Bio-Techne Corporation?
Bio-Techne Corporation's fiscal year ends in June.
Where is Bio-Techne Corporation based?
Bio-Techne Corporation's address is: 614 McKinley Place N.E., Minneapolis, MN, United States, 55413
What is Bio-Techne Corporation's ISIN number?
Bio-Techne Corporation's international securities identification number is: US09073M1045
What is Bio-Techne Corporation's CUSIP number?
Bio-Techne Corporation's Committee on Uniform Securities Identification Procedures number is: 09073M104

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site